The treatment of myocardial ischemia using gene therapy is a rather novel but promising approach. Gene delivery to target cells may be enhanced by using double-targeted delivery systems simultaneously capable of extracellular accumulation and intracellular penetration. With this in mind, we have used low cationic liposomes-plasmid DNA complexes (lipoplexes) modified with cell-penetrating transactivating transcriptional activator (TAT) peptide (TATp) and/or with monoclonal anti-myosin monoclonal antibody 2G4 (mAb 2G4) specific toward cardiac myosin, for targeted gene delivery to ischemic myocardium. In vitro transfection of both normoxic and hypoxic cardiomyocytes was enhanced by the presence of TATp as determined by fluorescence microscopy and ELISA. The in vitro transfection was further enhanced by the additional modification with mAb 2G4 antibody in the case of hypoxic, but not normoxic cardiomyocytes. However, we did not observe a synergism between TATp and mAb 2G4 ligands under our experimental condition. In in vivo experiments, we have clearly demonstrated an increased accumulation of mAb 2G4-modified TATp lipoplexes in the ischemic rat myocardium and significantly enhanced transfection of cardiomyocytes in the ischemic zone. Thus, the genetic transformation of normoxic and hypoxic cardiomyocytes can be enhanced by using lipoplexes modified with TATp and/or mAb 2G4. Such complexes also demonstrate an increased accumulation in the ischemic myocardium and effective transfection of
Introduction
Gene therapy is becoming an important strategy in the treatment of various diseases such as cancer, AIDS and cystic fibrosis. However, its success is limited mainly due to the lack of efficient delivery systems to target sites of interest, especially with systemic diseases, when systemic administration becomes the main route to reach such sites. Therefore, the outcome of gene therapy in vivo depends on the effective delivery of DNA-related drugs, either in the form of oligonucelotides (antisense ODN, siRNA) or entire genes (plasmid DNA (pDNA)) to their cellular site of action, and requires the development of effective delivery systems.
Although viral vectors have been the favorites for several clinical applications due to highly efficient intracellular DNA delivery, they suffer from immunogenicity, nonspecificity and inherent risks of complications such as interference with the activity of tissuespecific promoters. 1 Non-viral vectors have also been of great interest and widely studied as alternatives to viral vectors. 2 Among the non-viral vectors, cationic liposome-DNA complexes (lipoplexes) have been widely investigated in preclinical and clinical trials because their in vitro transfection efficiency is comparable to that of viral vectors, 3 although their use could be associated with nonspecificity and cytotoxicity.
Despite the recent advances with the non-viral gene delivery systems, gene therapy for the treatment of myocardial ischemia and myocardial infarction still constitutes a rather novel approach in cardiovascular medicine. 4, 5 However, the available data have already provided the evidence of a big potential for this approach. Thus, the idea of converting cardiac fibroblasts into skeletal muscle cells by forced expression of the MyoD gene was put forward and proven experimentally. 6 Lung grafts have been transfected ex vivo with a model construct, but future ameliorating ischemiareperfusion injury and rejection must be kept in mind. 7 Overexpression of the fibroblast growth factor-2 in the heart was shown to increase the resistance to ischemic injury in an isolated mouse heart model. 8 An enhanced expression of the VEGF gene was hypothesized to increase the resistance toward the ischemia by facilitating angiogenesis. 9 After it was found that the expression of HSP 70, a member of the family of heat-shock proteins, 10 correlates with the extent of myocardial protection after ischemia-reperfusion injury, gene transfer of HSP 70 was used to protect cardiac functions under ischemia and reperfusion. 11 Improved myocardial perfusion and functional recovery have also been observed after gene transfer of VEGF, 12 FGF 13 and HGF. 14 Taken together, all these results support promising opportunities for gene therapy of myocardial infarction using, in particular, cationic liposomes that may represent a convenient way to deliver genes to cardiac cells. 15 The transactivating transcriptional activator peptide (TATp, 11 amino acids), protein transduction domain of the TAT protein (86 amino acids) from HIV-1 has been shown to efficiently introduce various small molecules as well as large macromolecular therapeutics, such as DNA and proteins, into mammalian cells in vitro and in vivo. 16 A successful use of the TATp for enhanced intracellular delivery of various nanoparticulates, such as iron oxide nanoparticles, quantum dots, polymeric micelles and liposomes, including sterically stabilized liposomes was also demonstrated. 17 The modification with TATp allowed for the efficient intracellular delivery of lipoplexes, and their subsequent accumulation in the nuclear compartment with an enhanced recombination, which resulted in high expression of green fluorescence protein (GFP) in vitro and in vivo. 18, 19 On the other hand, the highly specific anti-myosin monoclonal antibody 2G4 (mAb 2G4) demonstrated an excellent ability to recognize and bind ischemic cells with damaged plasma membranes when intracellular myosin becomes exposed to the extracellular space and thus allows for the antibody binding. 20 This property of the anti-myosin antibody was successfully used for the delivery of antibody-bearing liposomes into the area of experimental myocardial infarction (EMI) 21 and even for cell protection against the hypoxic damage by 'plugging' the holes in cell membranes with anti-myosin antibodybearing liposomes. 22, 23 In the current study, the application of TATp-lipoplexes was extended to gene delivery to ischemic myocardium with a future goal of gene therapy of a myocardial infarct and other cardiac disorders. The TATp-lipoplexes were constructed with a low content of a potentially cytotoxic cationic lipid, dioleoyl-1,2-diacyl-3-trimethylammonium-propane (DOTAP), needed in our system just to better complex a negatively charged DNA. 18 pDNA encoding for GFP (pGFP) was used as a model gene therapeutic. The TATp-lipoplexes were further decorated with the anti-myosin mAb 2G4 for in vivo targeting to the ischemic heart. The 2G4-modified TATp-lipoplexes were tested in a cell culture system with rat cardiomyocytes and in an EMI model in rats.
Results

Preparation of TATp-lipoplexes
The formation of TATp-lipoplexes between TATpbearing liposome (TATp-liposome) and pDNA was confirmed by the electrophoresis on a 0.8% agarose gel (Figure 1a ). When complexed with TATp-liposomes, pDNA could not enter the gel because of the size restriction. The formation of plain lipoplexes between plain liposome without TATp and pDNA is also shown for comparison. All pDNA in plain and TATp-lipoplexes was retained in wells without the migration (lanes 3 and 5), indicating complete complexation of pDNA. The complexed pDNA was completely released from the plain lipoplexes after the treatment with Triton X-100 (lane 4). However, the release of the complexed pDNA from the TATp-lipoplexes was incomplete, leaving some pDNA in the well with a broad migration band (lane 6). As Triton X-100 does not interfere with the migration of free pDNA (lanes 1 and 2), this partial release indicates a tighter complexation of pDNA with TATp-liposome than with the plain liposome, probably due to the contribution of the cationic TATp to charge interaction with the anionic pDNA.
Size and zeta-potential of plain and TATp-liposome were measured before and after complexation with pDNA. The complex formation led to a moderate increase in size and decrease in zeta-potential ( Figure  1b) . Before complex formation, the liposome size was approx. 170 nm for both, plain liposomes and TATpliposomes. Upon complex formation with pDNA, the size increased to approximately 220 nm. The zetapotential of liposomes before complex formation was ca. 38 mV for both, plain liposome and TATp-liposomes. Upon the complex formation with pDNA, the zetapotential decreased to approximately 31 mV. The decreased zeta-potential can be explained by the partial charge neutralization upon complexation of the negatively charged pDNA with the cationic liposomes. Gene therapy using 2G4/TATp double-targeted lipoplexes YT Ko et al
We previously reported the microscopic structure of these lipoplexes. 18 The freeze-etching electron microscopy showed that the major fraction of the lipoplexes maintained an essentially spherical shape with a size of B200 nm, displaying convex and concave fracture planes typical of liposomal structure, and dotted boundaries characteristic of liposome-nucleic acid complexes.
In vitro transfection of normoxic and hypoxic cardiomyocytes
The in vitro transfection efficacy of various lipoplexes was assessed with rat cardiomyocytes H9C2. Initially, the H9C2 cells were treated with the TATp-lipoplexes or plain lipoplexes in hypoxic conditions. For comparison, cells in normoxic conditions were treated with the same formulations. The transfection outcome was determined qualitatively by the visualization of GFP with the fluorescence microscopy. The microscopy parameters were set so that no green signal was observed from non-treated cells and all images were acquired with the same parameters. Semiquantitation of the images was also carried out (BioQuant, Nasheville, TN, USA) ( Figure 2 ). Normoxic cells treated with plain lipoplexes showed low level of green fluorescence, indicating a minimal transfection outcome via a TATp-independent pathway. This observation of TATp-independent transfection was consistent with the data shown earlier with NIH/3T3 fibroblasts. 18 Cationic lipid DOTAP, although low in content, could still be responsible for the TATpindependent transfection in normoxic cells. Hypoxic cells treated with plain lipoplexes displayed even greater TATp-independent transfection. In addition to the DOTAP-mediated transfection, hampered integrity of cell membranes in hypoxic cells could also result in more transfection via TATp-independent pathways.
Noticeably brighter green fluorescence (enhanced transfection) was observed for the cells treated with TATp-lipoplexes at both normoxic and hypoxic conditions. The enhanced transfection with TATp-lipoplexes indicated that intracellular delivery mediated by TATp played an important role in the transfection of hypoxic as well as normoxic cells.
The in vitro transfection efficiency of the TATplipoplexes in ischemic cardiomyocytes was also quantitatively assessed by ELISA ( Figure 3 ). The results were quite consistent with the qualitative microscopy data. Gene therapy using 2G4/TATp double-targeted lipoplexes YT Ko et al
The level of GFP expression was significantly higher with TATp-lipoplexes than with plain lipoplexes regardless of the incubation conditions. The TATp-lipoplexes led to the GFP expression more than twice as high as the level of expression with the plain lipoplexes at normoxic and hypoxic conditions. However, the effect of the anti-myosin mAb 2G4 varied with the incubation conditions. In normoxic cells, no significant enhancement in GFP expression by mAb 2G4 modification was observed with either plain lipoplexes or TATp-lipoplexes. In hypoxic cells, however, a significant enhancement in GFP expression was obtained by mAb 2G4 modification of both plain lipoplexes and TATp-lipoplexes. 2G4-modified plain lipoplexes resulted in a fourfold higher GFP expression than unmodified plain lipoplexes. 2G4-modified TATplipoplexes resulted in almost twofold higher GFP expression than unmodified TATp-lipoplexes. This can be explained by the additional mAb 2G4-mediated targeted delivery of the lipoplexes to the hypoxic cells because of the better binding of the lipoplexes with the hypoxically damaged cells due to the exposure of the intracellular cardiac myosin. The enhanced transfection by antibody modification was specific to anti-myosin antibody, as shown by the absence of enhancement with the nonspecific isotype-matching antibody UPC10 (Figure 3) .
Interestingly, 2G4-modified TATp-lipoplexes could not provide better transfection than 2G4-modified plain lipoplexes in hypoxic cells, revealing that the effect of TATp on transfection of the hypoxic cells did not add much in the presence of 2G4 antibody.
The TATp-liposomes with a low content of a positively charged lipid, that is, 10 mol% of DOTAP, were non-toxic for the NIH/3T3 cells even after 24 h of incubation. 18 In this study, we have also evaluated the cytotoxicity of the TAT-lipoplexes with or without 2G4 modification toward the normoxic and hypoxic H9C2 cardiomyocytes. Both TATp-lipoplexes and 2G4-modified TATp-lipoplexes showed no toxicity up to lipid concentration of 200 mg/ml (1.5 mg/ml of pDNA, 31 mg/ml of DOTAP) at both hypoxic and normoxic conditions (Figure 4 ).
In vivo transfection in EMI model
The feasibility of the in vivo gene delivery to ischemic heart using 2G4-modified TATp-lipoplexes was demonstrated in an EMI model in rat. The efficacy of lipoplexspecific delivery into the ischemic area was first assessed rather than the efficiency of the GFP expression because of the relatively short experimental time with infarcted animals. For this purpose, all lipoplexes were fluorescently labeled with rhodamine-phosphatidylethanolamine (Rh-PE), and the accumulation of the lipoplex-associated fluorescence over the normal and ischemic areas of the heart after an i.v. injection was investigated by fluorescence microscopy. At the end of the experiment, Unisperse Blue (USB) dye was injected i.v. following a re-occlusion to demarcate the normal area from the ischemic area of the heart. When 2G4-modified TATp-lipoplexes were administered, the bright red rhodamine fluorescence was readily found in the ischemic area, whereas significantly lower red fluorescence was observed in the normal heart area ( Figure 5 ). Semiquantitative analysis of the images (ImageJ, NIH) revealed that the ischemic area was more than twice as bright as the normal area. This preferential accumulation was not observed with control animals treated with TATp-lipoplexes modified with the nonspecific antibody UPC10 ( Figure 5 ), indicating namely that mAb 2G4 mediated the in vivo accumulation of the lipoplexes in the ischemic area of the heart. The GFP expression in different areas of the heart was then assessed after the administration of 2G4-modified TATp-lipoplexes. The formulation was injected by i.v. infusion at the rate of 50 ml/min and the GFP expression was investigated with the fluorescence microscopy after 24 h. The bright fluorescence was found only in the ischemic region of the left ventricle, whereas low fluorescence was observed in other regions ( Figure 6 ). This localized GFP expression clearly indicates that the preferential accumulation of 2G4-modified TATp-lipoplexes in the ischemic area led to the enhanced transfection of cardiomyocytes in this area.
Discussion
In this study, we constructed the double-targeted lipoplexes with the use of TATp-and myosin-specific mAb 2G4, aiming for the combination of extracellular and intracellular targeting of ischemic areas of the heart. Such constructs were expected to accumulate in the ischemic areas through the mAb 2G4-mediated targeting in addition to the enhanced permeability and retention effect. The cell-penetrating peptide, TATp, was then Gene therapy using 2G4/TATp double-targeted lipoplexes YT Ko et al expected to facilitate the intracellular delivery of the lipoplex formulation and the corresponding plasmid to the inside of the ischemic cardiomyocytes for better transfection. The efficacy of the double-targeted lipoplexes was evaluated in vitro with hypoxic cardiomyocytes and in vivo in rats with the EMI model using pDNA encoding for the GFP.
The effect of targeting by TATp and 2G4 was clearly shown in cell culture experiments. In normoxic cells where the intracellular myosin is not exposed, the presence of anti-myosin antibody 2G4 provided no transfection enhancement, whereas the presence of TATp resulted in a significantly better transfection (increased GFP expression). The TATp-lipoplexes led to a threefold higher GFP expression than plain lipoplexes at normoxic conditions.
In hypoxic cells where the plasma membranes are damaged and myosin is partially exposed, 20 the presence of the anti-myosin antibody 2G4 provided a significant transfection enhancement in addition to the enhancement associated with TATp. The 2G4-modified TATplipoplexes led to a fourfold higher GFP expression, whereas TATp-lipoplexes without mAb 2G4 led to only a twofold higher GFP expression than plain lipoplexes. It is interesting to note that the 2G4-modified plain lipoplexes without TATp provided the same level of gene expression as the double-targeted 2G4-modified TATp-lipoplexes, suggesting that 2G4 antibody plays a dominant role in transfecting hypoxic cells under our experimental conditions. Although TATp alone in the absence of 2G4 antibody could provide enhanced transfection, it seemed that 2G4 antibody is so efficient with hypoxic cells that 2G4 alone could provide the same level of transfection as the combination of 2G4 and TATp. This suggests that the use of intracellular targeting with TATp may not be necessary for in vitro transfection of hypoxic cells, which have compromised plasma membranes allowing for a very effective anti-myosin antibody-mediated targeting. However, we can foresee that the combination of TATp and specific antibodies could be highly beneficial for other cardiac pathologies not associated with damaged cell membranes. In vivo accumulation of 2G4-modified transactivating transcriptional activator peptide (TATp)-lipoplexes upon intravenous injection was determined using the experimental myocardial ischemia model in rats. The Unisperse Blue (USB) dye demarcates the normoxic area from the ischemic area (inset). The fluorescent-labeled 2G4-modified TATp-lipoplexes was readily found in ischemic area, whereas no formulation was found in normoxic area. However, this preferential accumulation was not observed with nonspecific antibody UPC10-modified TATp-lipoplexes. See experimental methods for details. 
Gene therapy using 2G4/TATp double-targeted lipoplexes YT Ko et al
Although lipoplexes have been widely explored because of their high transfection efficiency in cell culture systems, they have not shown any significant therapeutic efficacy for in vivo applications due to their instability and toxicity upon i.v. administration. 24 When injected intravenously, lipoplexes interact with blood components to form aggregates and rapidly accumulate mainly in the capillary bed of the lung. Reticulo-endothelial system (RES) organs clear the lipoplexes released from the lung deposition. As a result, the lipoplexes are cleared from blood circulation in a few minutes. Thus, in vivo use of lipoplexes, although increasing, will probably be limited to the application for gene delivery to the lung and liver. 25 We have recently demonstrated the in vivo application of TATp-lipoplexes in whole animals bearing LLC cells, 18 where the formulation was directly injected into tumor tissues. In the current study, we demonstrated the feasibility of in vivo use of the TATp-lipoplexes following i.v. administration. In this case, TATp-lipoplexes were sterically stabilized by the incorporation of PEG3400-PE. The incorporation of polyethylene glycol (PEG)-PE into the TATp-lipoplexes was expected to suppress nonspecific interactions with non-targeted tissues and thus provide in vivo stability during blood circulation following i.v. injection until such lipoplexes accumulated in the areas with the increased vascular permeability through the combination of the enhanced permeability and retention effect with the active ligand-mediated targeting. The stabilized TATplipoplexes could be targeted to the myocardium by the disease-specific mAb (to ischemic myocardium with the anti-myosin mAb 2G4). The incorporation of PEG-PE and the attachment of 2G4 antibody to TATp-lipoplexes were accomplished simultaneously by the so-called 'micelle transfer' procedure, 26, 27 which provides simultaneous transfer of antibody-coupled micelles to liposome with negligible leakage. Thus, it is unlikely that the antibody coating affect DNA loading. It was also shown that the procedure did not lead to any significant changes in the particle size. 28 With 50% efficiency of antibody-to-activated PEG-PE (p-nitrophenylcarbonyl-polyethylene glycol-phosphatidyl ethanolamine (pNP-PEG-PE)) conjugation and close to 100% efficiency of the micelle transfer procedure, the final construct would contain approximately 3 mol% of PEG-PE, which provides good steric stabilization and sufficient in vivo stability. 18 The conjugation of antibodies by the procedure resulted in about 100 antibodies per lipoplex (liposome) particle corresponding to about 85 mg antibody per micromole phospholipids. As shown earlier, 28 ,29 the antibody density could effectively direct the construct to target sites, infarcted myocardium in this case, upon i.v. administration.
The promise of the antibody-modified TATp-lipoplexes for in vivo application was clearly shown by the preferential accumulation of the mAb 2G4-targeted construct into the ischemic areas of the infarcted rat heart. In the subsequent GFP expression experiment, this accumulation was proven to lead to an increased gene expression in the ischemic cardiomyocytes.
Thus, in vivo experiments with the EMI model clearly demonstrated a preferential accumulation of the doubletargeted lipoplexes in the ischemic area of the infarcted rat myocardium following i.v. administration and a better transfection outcome. In this study, we have used the pGFP as a model gene. It certainly would be of great interest to see the in vivo therapeutic efficacy of the antibody-targeted TATp-lipoplexes loaded with therapeutic genes.
In conclusion, the genetic transformation of cultured hypoxic cardiomyocytes can be significantly enhanced by TATp-lipoplexes. The additional modification with the anti-myosin mAb 2G4 further increases the transfection efficiency of the TATp-lipoplexes. Such lipoplexes were able to increasingly accumulate in the infarcted area of the heart. Specific antibody-modified TATplipoplexes provide a promising approach to gene therapy of the myocardium.
Materials and methods
Materials
pDNA encoding for the GFP (pGFP) was purchased from Elim Biopharmaceuticals (Hayward, CA, USA). 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), DOTAP, PE, PEG-PE and 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) ammonium (Rh-PE) were purchased from Avanti Polar Lipids (Alabaster, AL, USA). All the chemicals were of the reagent grade.
Preparation of 2G4-modified TATp-lipoplexes
The TATp (11-mer: TyrGlyArgLysLysArgArgGlnArgArgArg; 1560 Da) was coupled to the spacerpNP-PEG1000-PE as described before 29, 30 to obtain TATp-PEG-PE conjugate. The TATp-liposome was then prepared by rehydration of the lipid film comprising POPC, cholesterol, DOTAP, TATp-PEG-PE (6:3:1:0.05 mol/mol) followed by extrusion through membranes with a 200 nm pore size. Control plain liposomes without TATp were prepared with PEG-PE instead of TATp-PEG-PE. The pDNA was mixed with the TATp-liposome at the (+/À) charge ratio of 10 to obtain TATp-liposome-pDNA complexes (TATp-lipoplexes). The anti-myosin antibody 2G4 was first conjugated to the micelle of pNP-PEG3400-PE and then inserted into the preformed TATp-lipoplexes by the 'micelle transfer' procedure. 26, 27 Briefly, an amount of pNP-PEG3400-PE corresponding to 3 mol% of total lipids was hydrated in sodium citrate-buffered saline (5 mM, pH 5.0) and mixed with mAb 2G4 in sodium borate buffer (50 mM, pH 9.0) at a molar ratio of 40:1, corresponding to 169 mg antibody/mmol phospholipids. The mixture was incubated overnight and then dialyzed against 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid-buffered saline (10 mM, pH 7.4) with a cellulose ester membrane of MWCO 250 000 Da (Spectrum Medical Industries, Los Angeles, CA, USA) at 4 1C. The mAb 2G4-PEG3400-PE conjugate (as loose micelles) was then added to the preformed TATp-lipoplexes and incubated overnight at 4 1C, resulting in the quantitative association of mAb 2G4-PEG-PE with lipoplexes and formation of mAb 2G4-modified TATp-lipoplexes.
The resulting lipoplexes were characterized with respect to complex formation, size distribution and zeta-potential. Complex formation was confirmed by agarose gel electrophoresis. Electrophoresis was performed using the E-Gel electrophoresis system (Invitrogen, Carlsbad, CA, USA). A precast 0.8% E-Gel cartridge was pre-run for 2 min at 60 V and 500 mA followed by the loading of 1 mg of pDNA. The size distribution and zeta-potential of various preparations Gene therapy using 2G4/TATp double-targeted lipoplexes YT Ko et al were determined by quasi-elastic light scattering technique using a Zeta Plus Analyzer (Brookhaven Instruments, Brookhaven, NY, USA). The efficiency of antibody conjugation and transfer was assessed using a fluorescently labeled immunoglobulin G antibody.
In vitro transfection
The rat cardiomyocytes H9C2 were grown in Dulbecco's modified Eagle's medium supplemented with 10% fetal bovine serum on coverslips in six-well plates to B60% confluency. The cells were treated by replacing the media with 2 ml of the serum-free Dulbecco's modified Eagle's medium containing the TATp-lipoplexes at the final pDNA concentration of 1 mg/ml per well (corresponding to 22 mg of DOTAP and 140 mg of POPC) and then incubated at 37 1C in either normoxic or hypoxic (95% N 2 and 5% CO 2 ) conditions for 2 h. After removing the transfection media, the cells were washed and incubated in Dulbecco's modified Eagle's medium (with fetal bovine serum). After 48 h incubation, the coverslips were washed and mounted on slide glasses with the mounting media (ProLong Antifade; Invitrogen). The GFP expression was visualized using fluorescence microscopy (BX61; Olympus, Melville, NY, USA) with a fluorescein isothiocyanate filter and quantified using image analysis software (BioQuant). Images were segmented by threshold value so that only cells were selected and backgrounds were excluded. The level of GFP expression was assessed as average fluorescence intensity of the selected pixels.
To complement the qualitative fluorescence microscopy analysis, we also evaluated the relative content of GFP expression by ELISA. The rat H9C2 cardiomyocytes grown in six-well plates were treated as above. After washing with cold PBS (2 ml Â 2), 400 ml of the lysis buffer (M-Per; Pierce Biotechnology, Rockford, IL, USA) was added to the cells and incubated for 5 min at room temperature while shaking. The cell lysates were centrifuged for 1 h at 14 000 g and 4 1C. The supernatants were then transferred to new vials. A sandwich ELISA for GFP was conducted with 100 ml of lysate. Briefly, samples were incubated for 1 h on goat anti-GFP coated plates (Reacti-Bind Anti-GFP plate; Pierce Biotechnology). Rabbit anti-GFP antibody (Invitrogen) was added to each well at a 1:1000 dilution and incubated for 1 h at room temperature. Goat anti-rabbit immunoglobulin G conjugated to the horse raddish peroxidase (HRP) enzyme (Promega, Madison, WI) was added to each well at a 1:2000 dilution and incubated for 1 h at room temperature. To each well, 100 ml of HRP substrate (Invitrogen) was added. After 5 min, 100 ml of H 2 SO 4 (2 N) was added to stop the reaction. The absorbance at 450 nm was measured for each well using a 96-well plate reader (Labsystem Multiscan MCC/340; Fisher Scientific Co., Pittsburgh, PA, USA).
Cytotoxicity assay
The H9C2 cells were seeded in 96-well plates and treated as above with 100 ml of lipoplex formulations containing up to 200 mg of POPC (corresponding to 32 mg of DOTAP and 1.4 mg of pGFP). After 48 h, 20 ml of CellTiter 96 Aqueous One solution (Promega) was added to each well and the plates were re-incubated for 2 h. The absorbance at 490 nm was measured for each well using a 96-well plate reader (Multiscan MCC/340; Fisher Scientific Co.). Relative cell viability was calculated by comparing the results from the experimental systems with the cells treated only with the medium as a control.
In vivo study with EMI model in rats
The procedure described elsewhere 31 was followed with modifications. Rats were anesthetized with ketamine (80 mg/kg) and xylazine (8 mg/kg). They were tracheostomized and ventilated with a Harvard rodent ventilator (Harvard Apparatus Co., Holliston, MA, USA) with room air at a rate of 46-50 strokes/min and at a tidal volume of B5 ml, which was adjusted individually according to thorax expansion. The heart was exposed with a left thoracotomy and the pericardium was dissected. A 4-0 nylon suture (Ethicon, Somerville, NJ, USA) was placed in the region of the proximal left anterior descending coronary artery toward the base of left ventricle. The suture was threaded through a small piece of polyethylene tubing to serve as a reversible snare occluder. Four subcutaneous limb leads were placed with needles and the ECG was continuously monitored with an electrocardiograph (PageWriter XLi; Hewlett-Packard, Palo Alto, CA, USA). Myocardial ischemia was induced by tightening the occlusion snare. After 30 min of coronary artery occlusion, the occlusion snare was released. For in vivo accumulation studies, 2G4-modified TATp-lipoplexes, containing 0.5 mol% of Rh-PE (fluorescent label), were injected through a femoral vein. After 30 min of circulation, the snare was retightened and 0.5 ml of 1:5 diluted USB (Ciba, Basel, Switzerland) was injected through the femoral vein to demarcate the occlusion-induced ischemic zone. USB stains the perfused normoxic tissues, whereas nonperfused ischemic zones remain unstained. For transfection experiments, 0.5 ml of 2G4-modified TATp-lipoplexes was infused over 10 min through a femoral vein. The injected dose corresponded to 14.0 mg of pGFP, 2.0 mg of POPC and 310 mg of DOTAP. The open chest was then closed tightly and ventilator was removed. At 24-48 h post-injection, animals were killed with CO 2 and the hearts were removed. The excised left ventricle was sliced perpendicular to its longitudinal axis at 2-3 mm thickness intervals. The slices were incubated in 4% paraformaldehyde overnight and then in 20% sucrose overnight at 4 1C. The slices were then immersed in Tissue-Tek OCT 4583 and frozen in ice-cold isopentane. The slices were sectioned at a thickness of 8 mm using a cryotome (TBS, Durham, NC, USA). The thin sections were analyzed with a fluorescence microscope (BX51; Olympus).
